Your shopping cart is currently empty

Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation. Abeprazan hydrochloride is a proton pump inhibitor (PPI) that acts by reducing gastric acid production and is used to treat gastric acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $56 | In Stock | In Stock | |
| 5 mg | $143 | In Stock | In Stock | |
| 10 mg | $212 | In Stock | In Stock | |
| 25 mg | $340 | In Stock | In Stock | |
| 50 mg | $461 | In Stock | In Stock | |
| 100 mg | $592 | In Stock | In Stock | |
| 200 mg | $783 | - | In Stock |
| Description | Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation. Abeprazan hydrochloride is a proton pump inhibitor (PPI) that acts by reducing gastric acid production and is used to treat gastric acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers. |
| In vitro | The mechanism of action of Abeprazan hydrochloride involves reversible binding to H+, K+-ATPase, and, unlike PPIs, it does not require an acidic environment for activation [1]. |
| In vivo | Abeprazan hydrochloride effectively suppresses acid secretion in a dose-responsive manner, demonstrating equal or superior efficacy to vonoprazan, an established P-CAB, across multiple in vivo studies including pylorus-ligated rats, lumen-perfused rat models, and Heidenhain pouch dog models[1]. |
| Synonyms | Fexuprazan hydrochloride, DWP14012 hydrochloride |
| Molecular Weight | 446.87 |
| Formula | C19H18ClF3N2O3S |
| Cas No. | 1902954-87-3 |
| Smiles | Cl.CNCc1cn(c(c1OC)-c1ccc(F)cc1F)S(=O)(=O)c1cccc(F)c1 |
| Relative Density. | 1.31g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (89.51 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.48 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.